Open AccessRivaroxaban Experience at Tertiary Care Centre in Saudi Arabia:A Retrospective Observational Study
Author(s) -
Muhammad Riazuddin,
Mohamed Ahmed Mpharm,
Muhammad Imran Butt,
Mohammed Abufarhaneh,
Shahid Khan,
Omar Emadi,
Mohammed Alkasab,
Haifa Fahad Alsudairy,
Khalid Oqalaa Alshammari,
Aamir Sheikh,
Abdulaziz Alrashed
Publication year - 2020
Publication title -
galen medical journal
Language(s) - English
Resource type - Journals
eISSN - 2588-2767
pISSN - 2322-2379
DOI - 10.31661/gmj.v9i0.1882
Subject(s) - rivaroxaban , medicine , pulmonary embolism , thrombosis , atrial fibrillation , deep vein , retrospective cohort study , adverse effect , observational study , surgery , warfarin
Background: Atrial fibrillation (AF) and Venous Thromboembolism (VTE) are significant causes of morbidity and mortality. Direct oral anticoagulants (DOACs) are as effective as vitamin K antagonists (VKAs) with a propensity to cause less major bleeding. This study aimed to assess the safety and effectiveness of rivaroxaban in routine clinical practice in a large tertiary referral center in Saudi Arabia.Materials and Methods: In this study, patients who received rivaroxaban at a tertiary referral hospital were included in this study. All adverse events were recorded, including major bleeding, non-major bleeding events, symptomatic thromboembolic events (deep vein thrombosis, pulmonary embolism) and all-cause death.Results: A total of 509 patients were prescribed rivaroxaban during the study period. The most common indication for rivaroxaban was non-valvular AF (65.3%) and VTE (34.7%). The mean age was 60.4 ± 16.4 years, and 50.8% were female. The median CHA2DS2-Vasc score was 2.1 in patients on rivaroxaban for non-valvular AF. Bleeding occurred in 72 (14.1%) patients, of which 20 (3.9%) had major bleeds. Thrombosis events occurred in 13 (2.5%) patients in the overall cohort. Fourteen (2.7%) patients died during the study, including a case of fatal bleeding secondary to rivaroxaban.Conclusion: This study describes the use of rivaroxaban in a broad patient population in clinical practice in the Middle East. The overall bleeding and thrombosis rates in this study were comparable to those seen in major clinical trials.